Only one phase 1 trial was registered in ClinicalTrials.gov (NCT04887935), which aims to investigate the safety of dapagliflozin, one type of SGLT2 inhibitor, for men considered at high risk of prostate cancer. Here, SLC5A2 is linked to Familial prostate cancer.